Jun. 4 at 9:22 PM
BTIG reiterated
$LQDA Buy;
$59 and said: LQDA strength today can likely be attributed to the Supreme Court issuing a unanimous opinion in the Hikma vs. Amarin case, ruling in favor of Hikma.
$AMRN $UTHR MNKD INSM
BTIG added—We believe this ruling could limit the downside risks if LQDA were to not prevail in the '327 lawsuit, and there has been some speculation that the Judge presiding over the '327 trial was potentially waiting for this SCOTUS decision before deciding the '327 trial.
We would still expect some volatility in LQDA shares if an unfavorable '327 verdict is delivered (discussed below).
That said, this new Hikma v. Amarin SCOTUS precedent could make it difficult for UTHR (Neutral) to sue LQDA for induced infringement in that outcome and could allow LQDA to carry forward with a "PAH only" skinny label launch of Yutrepia, if needed.
